Advertisement FDA approves Gore C3 Delivery System: WL Gore & Associates - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA approves Gore C3 Delivery System: WL Gore & Associates

WL Gore & Associates has received the US Food and Drug Administration (FDA) approval for Gore C3 Delivery System, which is used to deploy the Gore Excluder AAA Endoprosthesis as minimally invasive treatment for patients with abdominal aortic aneurysm (AAA).

The GORE C3 Delivery System allows physicians and interventionalists to reposition the Gore Excluder Device before the final release of the delivery catheter.

The deployment control of the system provides the physician with increased confidence in treating challenging anatomies and also offers cannulation options.

Gore Aortic Business Unit leader David Abeyta said that the Gore C3 Delivery System for the Gore Excluder Device has shown a high level of performance and has demonstrated that it will provide physicians with added confidence and control during endovascular procedures.